Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.040
-0.020 (-1.89%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $64.05 million. The enterprise value is -$42.68 million.

Market Cap 64.05M
Enterprise Value -42.68M

Important Dates

The next estimated earnings date is Tuesday, May 13, 2025, before market open.

Earnings Date May 13, 2025
Ex-Dividend Date n/a

Share Statistics

Pyxis Oncology has 61.59 million shares outstanding. The number of shares has increased by 46.46% in one year.

Current Share Class 61.59M
Shares Outstanding 61.59M
Shares Change (YoY) +46.46%
Shares Change (QoQ) +0.88%
Owned by Insiders (%) 6.25%
Owned by Institutions (%) 33.98%
Float 44.34M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 3.76
Forward PS n/a
PB Ratio 0.52
P/TBV Ratio 0.54
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.17.

Current Ratio 7.49
Quick Ratio 7.18
Debt / Equity 0.17
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -62.75% and return on invested capital (ROIC) is -28.46%.

Return on Equity (ROE) -62.75%
Return on Assets (ROA) -24.77%
Return on Invested Capital (ROIC) -28.46%
Return on Capital Employed (ROCE) -47.00%
Revenue Per Employee $366,955
Profits Per Employee -$1.76M
Employee Count 44
Asset Turnover 0.10
Inventory Turnover n/a

Taxes

Income Tax -2.16M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -75.81% in the last 52 weeks. The beta is 1.17, so Pyxis Oncology's price volatility has been higher than the market average.

Beta (5Y) 1.17
52-Week Price Change -75.81%
50-Day Moving Average 1.09
200-Day Moving Average 2.43
Relative Strength Index (RSI) 50.42
Average Volume (20 Days) 542,009

Short Selling Information

The latest short interest is 7.13 million, so 11.58% of the outstanding shares have been sold short.

Short Interest 7.13M
Short Previous Month 7.34M
Short % of Shares Out 11.58%
Short % of Float 16.08%
Short Ratio (days to cover) 14.99

Income Statement

In the last 12 months, Pyxis Oncology had revenue of $16.15 million and -$77.33 million in losses. Loss per share was -$1.32.

Revenue 16.15M
Gross Profit 15.67M
Operating Income -65.57M
Pretax Income -57.80M
Net Income -77.33M
EBITDA -62.59M
EBIT -65.57M
Loss Per Share -$1.32
Full Income Statement

Balance Sheet

The company has $126.93 million in cash and $20.20 million in debt, giving a net cash position of $106.73 million or $1.73 per share.

Cash & Cash Equivalents 126.93M
Total Debt 20.20M
Net Cash 106.73M
Net Cash Per Share $1.73
Equity (Book Value) 120.75M
Book Value Per Share 2.01
Working Capital 114.76M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$57.67 million and capital expenditures -$237,000, giving a free cash flow of -$57.91 million.

Operating Cash Flow -57.67M
Capital Expenditures -237,000
Free Cash Flow -57.91M
FCF Per Share -$0.94
Full Cash Flow Statement

Margins

Gross Margin 97.06%
Operating Margin -406.11%
Pretax Margin -492.35%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -46.46%
Shareholder Yield -46.46%
Earnings Yield -120.73%
FCF Yield -90.41%

Analyst Forecast

The average price target for Pyxis Oncology is $9.20, which is 784.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.20
Price Target Difference 784.62%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) 40.82%
EPS Growth Forecast (5Y) -3.11%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Pyxis Oncology has an Altman Z-Score of -0.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.27
Piotroski F-Score 2